TMCnet News
Research and Markets: Breast Cancer Drug Pathway Analyzer 2014DUBLIN --(Business Wire)-- Research and Markets (http://www.researchandmarkets.com/research/x74n6m/breast_cancer) has announced the addition of the "Breast Cancer Drug Pathway Analyzer 2014" report to their offering. There are today at least 532 targeted molecular therapies known to affect more than 253 specific intracellular signaling pathways for the treatment of breast cancer. The rational for this plethora of treatment strategies is based on our increasing understanding of the 290 drug targets that are included in this drug-pathway analyzing tool. No less than 287 of these have been recorded with mutations and 49 drug targets have mutations which have been causally implicated in cancer. Pathway Coverage
The continuous identification of drug targets and pathways that are altered in cancer is not only crucial for our understanding of cancer biology, but also to search for new targets for early diagnosis and improved treatment designs. Consequently, it has never before been as important to rapidly translate systems biology of disease and therapeutics to actionable pipeline decisions to ensure that the optimal market conditions exist by the time a candidate drug is commercialized. You Use this Analyzer Tool in Breast Cancer to:
For more information visit http://www.researchandmarkets.com/research/x74n6m/breast_cancer
|